Index

Note: Page numbers in italics refer to Figures; those in bold to Tables

ACEIs see angiotensin converting enzyme inhibitors (ACEIs)
acquired/situational HSDD 57
ADAM see androgen deficiency in aging males (ADAM)
adult male genitourinary tract 8
adult psychosexual development tasks 3
ageing and sexuality
drugs and polypharmacy 87–8
education, health professional 88
help-seeking behaviour 88
illness, physical effects of 87
physical effects of 86–7
psychiatric illness and dementia 87
sexual activity, older people 86
social effects 88
alpha-blockers 53
5-alpha reductase inhibitors 53
alprostadil 70
American Psychiatric Association (APA) 93
AMH see anti-Müllerian Hormone (AMH)
androgen deficiency in aging males (ADAM) 40
angiotensin converting enzyme inhibitors
(ACEIs) 53, 69
angiotensin receptor blockers (ARBs) 53, 69
anti-androgens 53
antidepressants 48
anti-Müllerian Hormone (AMH) 5
anti-oestrogens 53
APA see American Psychiatric Association (APA)
ARBs see angiotensin receptor blockers (ARBs)
arteriography 69
atenolol 53
balanitis
causes 25
clinical features and management 26
balanoposthitis 25
behavioural addictions 94
benign prostatic hypertrophy (BPH) 68, 76
benzodiazepines 52
bibliotherapy and internet-based programmes
online educational tools 119
binocular vision 5
clothed male naked male (CMNM) 90
cognitive behavioural therapy (CBT) 49, 65
collagenase clostridium histoliticum (Xiaflex) injections 72
colour duplex Doppler ultrasound testing 41
comprehensive sexual interview questions 62–3
sexual activity 61
computerized tomography (CT) 39
contact allergies 27
coronary heart disease (CHD) 69
Decreased Sexual Desire Screener (DSDS) 38
dehydroepiandrosterone (DHEA) 36
delayed ejaculation
acquired delayed ejaculation 75
lifelong delayed ejaculation 75
dementia 87
depression 87
desire, excitation, orgasm, resolution (DEOR) model 15
deviant desires website 91
diagnostic and statistical manual of mental disorders (DSM V) 44–5, 55
diagnostic genital biopsy 27
digital inflection rigiometer (DIR) 41
dihydrotestosterone (DHT) 5
dimorphic wiring 5
disorders of sex development (DSD) 4
disorders of sexual preference 97
distress 64
dopamine agonist agents 58
dopamine β-hydroxylase 9
drugs, sex offender treatment, 98
dSD see disorders of sex development (DSD)
DSDS see Decreased Sexual Desire Screener (DSDS)
dynamic infusion
cavernosometry/cavernosography 69
dysaesthesia syndrome 28
dysmorphia 28
dysmorphophobia, diagnosis of 28
eczema 24, 27
education 64–5
effective communication 114
ejaculation 8
ejaculatory inevitability 9
electrocardiogram (ECG) 40
electroencephalogram (EEG) 39
emission 8
endocrine disorders
men, testosterone
hypogonadism, causes of 35
investigations 35–6
management 36
physiology 34
symptoms and signs 34–5
women, testosterone
diabetes 37
oestrogens 36–7
thyroid disorders 37
erect circumcision penis 9
erectile dysfunction (ED) 52
cardiovascular disease and 69
initial assessment
physical examinations 68
sexual history 68
laboratory testing 68
lifestyle management
cardiovascular drugs 69
drug-induced ED 69
hormonal causes 69
non-responders to PDE5 inhibitors 70
oral pharmacotherapy 69–70
psychossexual counselling and therapy 69
vacuum erection devices 70
penile erection 68
second-line treatment
intracavernous injection therapy 70–71
intrarethral alprostadil 71
specialized investigations 69
third-line treatment
penile prosthesis 71–2
peyronie’s disease 72
treatment objectives 69
erect 8
ethnic and cultural aspects, sexuality
dyspareunia and vaginismus 102
genital surgeries and modifications 101–2
heterosexual men (masculine socialization) 102–3
hymen dilemmas 102
multiethnic multicultural context 103
rapid ejaculation 102
vaginal and penile practices 102
excitation 8
excitement, plateau, orgasm and resolution (EPPR) model 9, 15
fear appeals 120
female
organism
anatomy and physiology 78
biological risk factors 78
diagnosis 79
disorders 77
evaluation 79
pathophysiology 78
prevalence 77–8
psychological and socio-cultural risk factors 78–9
treatment 79
sexual response cycles 13
female, anatomy and physiology
adult female genitalia
cervix 14
clitoris and vestibular bulbs 12
G-spot 14
labia 12, 14
orgasm 14–15
perineal glans 12
vagina 14
brain imaging 15
foetal genital development 12
puberty 12
sexual response cycle 15
female dermatoses
allergic and irritant contact dermatitis 32
atopic vulvitis 33
lichen sclerosus 31–2
pruritus vulvae 30
vulva, care of 30
vulval pain 30–31
vulvar psoriasis 32
vulval symptoms 30
female Mullerian duct system 12
female orgasm disorder (FOD)
anatomy and physiology 78
biological risk factors 78
diagnosis 79
evaluation 79
pathophysiology 78
prevalence 77–8
psychological and socio-cultural risk factors 78–9
treatment 79
female sexual arousal disorder (FSAD) 39
Female Sexual Function Index (FSFI) 39
female-to-male (FtM) 110
fMRI see functional magnetic resonance imaging (fMRI)
FOD see female orgasm disorder (FOD)
folic stimulating hormone (FSH) 35
forensic sexology
medical intervention 98–9
offending, deviance, disorder 96–7
sex offenders, assessment of 97–8
treatment algorithms 99
FSAD see female sexual arousal disorder (FSAD)
FSH see follicle stimulating hormone (FSH)
fourth body (FBC) 36
full blood count (FBC) 36
functional magnetic resonance imaging (fMRI) 11
gamma-butyrolactone (GBL) 105
gamma-hydroxybutyric acid (GHB) 105
gender dysphoria and transgender health
cross-sex hormones and gender affirming surgery 109–110
diagnostic codes, DSM and ICD 109
disorder and evolution 108
feminizing and masculinizing hormone therapy 110
fender affirming surgery 110–111
identity 109
medical treatment 109
treatment 108–9
gender identity disorder (GID) 4
gender similarities hypothesis 5
genital cutting 102
genital dermatoses 24
genital eczema 27
genital rashes dermatoses 24
genito pelvic pain/penetration disorder (GPPPD) 81
genito pelvic pain syndromes 81
gonadotrophin-releasing hormone (GnRH) 34
genital 4
GPPPD see genito pelvic pain/penetration disorder (GPPPD)
Harry Benjamin International Gender Dysphoria Association (HBIGDA) 108
health care practitioner (HCP) 21
homosexuality 97, 104–5
hormonal contraception 53
hormonal disturbances 57
hormone replacement therapy (HRT) 36, 115
hospital anxiety and depression scale (HADS) 40
HRT see hormone replacement therapy (HRT)
HSDD see hypoactive sexual desire disorder (HSDD)
human vulva, 64
hyperorsexual disorder 94
hypoactive sexual desire (HSD) 56
hypoactive sexual desire disorder (HSDD) 38, 55, 112
hypogonadism 34, 35
hypothyroidism 56
ICSB see impulsive/compulsive sexual behaviour (ICSB)
IELT see intravaginal ejaculation latency time (IELT)
impulsive/compulsive sexual behaviour (ICSB) 93
non-paraphilic ICSB 94
overpathologizing, sexual behaviour 94
pharmacological treatment 95
International Classification of Diseases (ICD)-10 43
International Diabetes Federation (IDF) 68
International Index of Erectile Function (IIEF) 68
intracavernosal injection 41
intracavernous injection test 69
intravaginal ejaculation latency time (IELT) 73
itch scratch cycle 31
Klinefelter’s syndrome 35
L-dopa 88
lesbian, gay, bisexual and transgender (LGBT) 88, 105
Leydig cells 5
LGBT see lesbian, gay, bisexual/transsexual (LGBT)
lichen planus 24
clinical features of 28
lichen sclerosus (LSc) 25–6
lower urinary tract symptoms (LUTSs) 53, 68
low sexual desire/interest (LSD/I) 56
LSc see lichen sclerosus (LSc)
luteinizing hormone (LH) 6, 34
LUTSs see lower urinary tract symptoms (LUTSs)
magnetic resonance imaging (MRI) 36, 39
major depression 56
male ejaculation and orgasm
anhedonic ejaculation 76
delayed ejaculation (see delayed ejaculation)
low ejaculate volume 76
painful ejaculation 76
POIS 75
premature ejaculation (see premature ejaculation)
ReGs 75
retrograde ejaculation 76
male, anatomy and physiology
adult genitalia
penis 7–8
brain imaging 11
erection, mechanism of 8–9
fetal genital development 7
puberty 7
sexual arousal 8
sexual excitation and arousal 8
male dermatoses
dysmorphophobia and dysaesthesia 28
genital rashes 24–5
inflammatory dermatoses 27
lichen planus 28
LSc 25–6
penile oedema 28–9
pre-malignant lesions 26–7
psoriasis 27–8
male towards female (MtF) 110
male, Wolffian duct system 12
Massachusetts Male Aging Study (MMAS) 68
medicated urethral system for erection (MUSE) 71, 72
medication and sexual dysfunction
drug-induced sexual dysfunction 51
descirone drugs 53
lipid-lowering drugs 54
LUTSs, drugs 53
psychotropic drugs
antidepressants 52
antipsychotic medication 51–2
anxiolytics 52
opioids 53
medications
sexual desire and arousal, women
pharmaceutical agents 66
placebo response 65, 67
sexual stimulation 65
menopause 15
mental illness 49
methamphetamine (MCA/TMA/MIAO) 105
methamphetamine (Crystal Meth/Tina) 105
3,4-methylenedioxymethamphetamine (MDMA) 48
mindfulness-based interventions (MBIs) 65
Mullerian Inhibiting Substance (MIS) 5
Mullerian system 4
National Coalition for Sexual Freedom (NCSF) 91
nocturnal penile tumescence and rigidity (NPTR) 41, 69
nocturnal phaloplethysmography (NPT) 48
NPTR see nocturnal penile tumescence and rigidity (NPTR)
objective sensory nerve testing 39
oestrogen deficiency 63
orgasm 9
pain assessment algorithm 84
paraphilia behaviour and disorders
exhibitionistic, frotteuristic and voyeuristic behaviour 91
fetishistic behaviour 90–91
paedophilia, forensic attention 91
problematic hypersexual behaviour 91
sadomasochistic behaviour 91
therapeutic options 92
paraphilias 44
paraphilic disorders 97
PDE5 Inhibitors 70
penile arteries 69
penile oedema, causes 29
penile papules 24
penile vaginal intercourse (PVI) 14
penis corpora cavernosal mechanism of erection 10
erectile process 9
medial and ventral aspects of 10
permission, limited information, specific suggestions and intensive therapy (PLISSIT model) 114
persistent genital arousal disorder (PGAD) 39–40, 52
peyronie’s disease (PD) 72
PGAD see persistent genital arousal disorder (PGAD)
pharmacological approach 58
pharmacotherapy 49
phosphodiestrase type 5 inhibitors (PDE-5is) 49
post-ejaculation refractory time (PERT) 8
post-organic illness (POIS) 75
premature ejaculation
acquired PE 73
drug treatment 74–5
lifelong PE 73
subjective PE 73–4
variable PE 74
primary ovarian disorder (POD) 36
Prince Albert 90
prolactin (PRL) 56
propranolol 53
prostate-specific antigen (PSA) 68
prostatitis/chronic pelvic pain syndrome 57
psoriasis 24
management 28
typical sites 28
psychiatric disorders and sexuality
evaluation 48–9
management, sexual dysfunction 49
mental illness 47
sexual dysfunction(s)
anxiety disorders and sexual functioning 47–8
mood disorders and sexual functioning 47
psychiatric disorders and sexual functioning 48
schizophrenia and 48
substance abuse and sexual functioning 48
trauma and sexual functioning 48
psychosocial development
adolescent development 2
adult development 3
childhood and adolescence, definition of 2
childhood development 2
cumulative view 1–2
factors 2–3
feminist views 2
Freud 4
law and culture 2
psychoanalytical views 1
psychosocial therapy (PST) 113
psychosocial therapy and couples therapy
behavioural techniques
pelvic floor exercises (Kegel exercises) 112
relaxation and breathing exercises 112
bibliotherapy, sex therapy 115
CIT 112
cognitive restructuring 112
combined therapies 115
dominance 115
mindfulness 113–14
multi-intervention sex therapy 115
myths 115
psychodynamic psychotherapy 112
resources 115–16
social/interpersonal skills 115
systemic therapy 114
psychotherapy 49
psycho(sexual) therapy 65
reparative therapies 105
restless genital syndrome (ReGs) 75
retroperitoneal lymphadenectomy (RLA) 76
Rigiscan 41
risk aware consensual kink (RACK) 106
safe, sane and consensual (SSC) 106
seborrhoeic dermatitis 27
selective serotonin reuptake inhibitors (SSRIs) 39, 52, 86
sensitive focus 113
sensitive sexual response system 60
serotonin-norepinephrine reuptake inhibitor (SNRI) 52
sereine cells 5
serum testosterone 34
sex
behaviour 97
formulation, biospsychosocial model 19
clinical assessment 18
history
consultation 16
couple/individual assessment 17
discomfot 16
ethical dilemmas 17
gender history 18
Index

sex (continued)
language 16
medication 18
past and current medical history 18
past and current relationship history 18
past and current sexual history 18
question/pattern/assessment tool 16
resources 16–17
sexual issues 16
sexual problem 18
therapy 49
Sex determining Region of the Y chromosome (SRY) 5
sex hormone binding globulin (SHBG) 34, 38
sexual desire
domains 62
men
aetiology 56–5
clinical evaluation 57
drive 55
epidemiology 56
HSDD 55
low sexual desire 55–6
motivation 55
treatment 57–8
wish 55
women
aetiology 59–61
comprehensivesexualinterview 61–63
contextualfactors 63
diagnosis 63–4
medicalhistory and physical and laboratory evaluations 63
treatment 64–7
sexual development
birth to puberty 5–6
DSD 4
intrauterine development 4–5
puberty
boy–man 6
girl–woman 6
sexual dimorphic nucleus of the preoptic area (SDN-POA) 5
sexual dysfunctions 87
antidotes 49
biopsychosocial working hypothesis 45
caregivers' perception 45
definition and descriptive diagnosis
DSM-V 45
generalcharacteristics, ICD-10 45
oral history 45
psychosocial factors 45
sexual confusion 45
sexual identity 45
sexual orientation 45
willingness to take part 45
sexual trauma/abuse 46
SHBG see sex hormone binding globulin (SHBG)
SIAD see sexual interest/arousal disorder (SIAD)
sildenafil 52
SNRI see serotonin-noradrenaline reuptake inhibitor (SNRI)
soft tip syndrome 41
spironolactone 53
squeeze technique 113
SSRIs see selective serotonin reuptake inhibitors (SSRIs)
STDs see sexually transmitted diseases (STDs)
STIs see sexually transmitted infections (STIs)
stop/start technique 113
substance abuse 49
substance use disorders 94
Tantric artefact 122
testosterone
deficiency 35
levels
female 6
male 5
testosterone deficiency syndrome (TDS) 34
testosterone-lowering drugs 99
testosterone replacement therapy (TRT) 36, 58, 69
thyroxin therapy 58
Tourette’s syndrome 39
tramadol 53
trans-rectal ultrasound (TRUS) 41
transurethral resection of prostate (TURP) 76
trazadone 52
tratment algorithm 61
TRT see testosterone replacement therapy (TRT)
TRUS see trans-rectal ultrasound (TRUS)
urological, psychological, organ-specific, infectious, neurological, tenderness (UPOINT(S)) system 82
vacuum erection devices (VEDS) 71
vasoactive intestinal peptide (VIP) 14
veno-occlusive mechanism 8
Vermeulen’s formula 35
VIP 25mcg/Phentolamine 2mgmixture 71
Wolffian system 4
women
HRF 37
sexual desire and arousal
aetiology 59–61
comprehensivesexualinterview 61–3
contextualfactors 63
diagnosis 63–4
medical history and physical and laboratory evaluations 63
treatment 64–7
testosterone 38
World Federation of Societies of Biological Psychiatry (WFSBP) 99
World Professional Association for Transgender Health (WPATH) 108